Internal Reference Number: FOI_9438
Date Request Received: 03/06/2026 00:00:00
Date Request Replied To: 25/06/2026 00:00:00
This response was sent via: By Email
Request Summary: Oncology Breast Cancer
Request Category: Researcher
| Question Number 1: I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel • Atezolizumab • Capivasertib • Capecitabine as a single agent • Carboplatin + Paclitaxel • Elacestrant • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab Monotherapy • Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Carboplatin + Paclitaxel + Pembrolizumab • Pertuzumab (Perjeta) + Trastuzumab (Herceptin) • Phesgo (Pertuzumab + Trastuzumab in a single injection) • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Trastuzumab deruxtecan (Enhertu) • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel • Trastuzumab emtansine (Kadcyla) • Any other active systemic anti-cancer therapy • Pembrolizumab subcutaneous injection | |
| Answer To Question 1: I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)23 • Abemaciclib + Fulvestrant less than 5 • Alpelisib + Fulvestrant 0 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only 0 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel 0 • Atezolizumab less than 5 • Capivasertib less than 5 • Capecitabine as a single agent 10 • Carboplatin + Paclitaxel 0 • Elacestrant less than 5 • Eribulin as a single agent or in combinationless than 5 • Everolimus + Exemestane less than 5 • Fulvestrant as a single agent less than 5 • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 19 • Palbociclib + Fulvestrant less than 5 • Parp Inhibitors (Olaparib/Talazoparib) 0 • Pembrolizumab Monotherapy less than 5 • Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide 0 • Carboplatin + Paclitaxel + Pembrolizumab less than 5 • Pertuzumab (Perjeta) + Trastuzumab (Herceptin) less than 5 • Phesgo (Pertuzumab + Trastuzumab in a single injection) 19 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 19 • Ribociclib + Fulvestrant less than 5 • Sacituzumab Govitecan less than 5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 6 • Trastuzumab deruxtecan (Enhertu) 7 • Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel 13 • Trastuzumab emtansine (Kadcyla) less than 5 • Any other active systemic anti-cancer therapy 13 • Pembrolizumab subcutaneous injection 0 | |
| Question Number 2: Please see attached | |
| Answer To Question 2: Please see attached To accompany this answer to question 2 please also see the documents listed below:  FOI 9438 - Q2.pdf | |
| Question Number 3: Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 3: The Trust is currently participating in one Clinical Trial for breast cancer: OPTIMA ; Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis; 48 participants recruited to date. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
